SEATTLE, Feb. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article looking at what makes algae a unique platform for cannabinoid production, as well as how the new agreement with Solarvest fits into FSD Pharma’s plans to become a leading cannabis producer.
FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRK: 0K9) recently signed a letter of intent with Solarvest BioEnergy Inc. to apply Solarvest’s algae platform to develop pharmaceutical grade cannabinoids. The move could dramatically disrupt current cannabinoid procurement methods by reducing the time, space, and costs associated with cannabis cultivation, particularly for medical cannabis subject to GMP certification standards.
Algae-based technologies have become a popular source of everything from alternative fuel to nutritional supplements. Like bacteria, algae can also be used to produce a wide range of bioactive recombinant proteins that can be leveraged to create a wide range of other molecules—including high-value therapeutic molecules. Cutting-edge researchers are looking at ways to create synthetic cannabinoids using these platforms as well.
Why Algae?
Most investors have probably heard of algae being used as a source of renewable energy since it consumes carbon dioxide and emits hydrogen and oxygen. A lesser known attribute of algae is that its chloroplasts are capable of manufacturing of bioactive recombinant proteins, which means that algae can be genetically-engineered to produce a wide range of therapeutic proteins that can be used to create millions of different molecules.
There are several benefits from algae-generated proteins:
- They are devoid of any known human pathogens.
- They are comparatively very inexpensive to produce.
- They produce consistent, high yield concentrations of final products.
- They can produce very complex therapeutic proteins.
- The production environment can be carefully controlled.
- Replicable processes expedite product development.
Solarvest BioEnergy Inc. has already introduced algae-generated omega-3 products into commercial markets and successfully created bone morphogenetic protein (BMP)—a high value complex compound used in orthopedic surgery to accelerate and enhance bone growth. The company has also built a portfolio of nearly 70 patents that have been filed and granted around numerous therapeutic areas.
Landmark Agreement
FSD Pharma and Solarvest plan to develop a research project for the purpose of developing a proof of concept that algae can express cannabinoids. Once the proof of concept is complete, the companies will enter into licensing agreements whereby Solarvest will provide exclusive worldwide rights to the cannabinoids to produce prescription drugs that can treat diseases affecting the nervous system—FSD Pharma’s primary target indication.
“If successful, this could dramatically disrupt current cannabis cultivation methods for medical purposes,” said FSD Pharma President Zeeshan Saeed. “It could reduce the majority of time, space, and costs associated with cannabis cultivation for medical purposes, specifically cannabis with GMP Certification. We are very pleased to collaborate with Solarvest on the development of promising alternative methods of cannabinoid production.”
In addition to the licensing agreement, Solarvest will pay a royalty fee to FSD Pharma on sales or licensing of any cannabinoids other than those targeting the nervous system, equal to five percent of net sales or net license fees. These royalties will be reduced to three percent after Solarvest has paid an aggregate of $3 million in royalty fees. These royalties could create a meaningful high-margin revenue stream if the technology is successful.
Looking Ahead
FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRK: 0K9) aims to become the largest licensed indoor hydroponic producer of cannabis in the world by converting a former Kraft Foods plant in Cobourg, Ontario into a state-of-the-art cultivation facility. The company’s recent agreement with Solarvest underscores this commitment to become a leading cannabis producer and demonstrates management’s outside-of-the-box thinking in that regard.
For more information, visit the company’s website at www.fsdpharma.com .
Please follow the link to read the full article: https://www.cannabisfn.com/fsd-pharma-looks-t...-in-algae/
About CFN Media
CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id...1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
Disclaimer
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
Frank Lane 206-369-7050 Flane@cannabisfn.com
